Evidence map›Paper›PMID 27478315›Full record

ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2016

Cancer incidence and mortality in Gansu province, 2012.

Yuqin Liu, Xiaodong Zhang, Lili Chen, Qin Zhao, Xiaojun Xia

Abstract read
In one paragraph

Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Serum TFF2 as a more reliable biomarker for gastric cancer and early gastric cancer: a cross-sectional population-based study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuqin LiuCentral Cancer Registry of Gansu, Gansu Cancer Hospital, Lanzhou 730050, China.
Xiaodong ZhangCentral Cancer Registry of Gansu, Gansu Cancer Hospital, Lanzhou 730050, China.
Lili ChenCentral Cancer Registry of Gansu, Gansu Cancer Hospital, Lanzhou 730050, China.
Qin ZhaoCentral Cancer Registry of Gansu, Gansu Cancer Hospital, Lanzhou 730050, China.
Xiaojun XiaCentral Cancer Registry of Gansu, Gansu Cancer Hospital, Lanzhou 730050, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePopulation-based cancer registration data in 2012 from all available cancer registries in Gansu province were collected by the Central Cancer Registry of Gansu. The numbers of new cancer cases and cancer deaths in Gansu province with compiled cancer incidence and mortality rates were estimated.

methodsIn 2015, data from 7 registries in Gansu province were qualified. The pooled data were stratified by area (urban/rural), gender, age group (0, 1.4, 5.9, 10.14, …, 85+) and cancer type. New cancer cases and deaths were estimated using age-specific rates and corresponding population of Gansu province in 2012. The Chinese census data in 2000 and Segi's population were applied for age-standardized rates. All the rates were expressed per 100,000 person-years.

resultsQualified 7 cancer registries (3 urban and 4 rural registries) covered 2,956,560 populations of Gansu province in 2012. The percentage of cases morphologically verified (MV%) and death certificate-only cases (DCO%) were 72.41% and 1.65%, respectively, and the mortality to incidence rate ratio (M/I) was 0.63. It was estimated that there were 575,600 new cancer cases and 331,300 cancer deaths in Gansu province in 2012. The incidence rate was 223.29/100,000 (244.14/100,000 in males and 201.50/100,000 in females), the age-standardized incidence rates by Chinese standard population (ASIRC) and by world standard population (ASIRW) were 208.95/100,000 and 206.41/100,000 with the cumulative incidence rate (0.74 years old) of 22.49%. The crude incidence rate in urban areas was equal to that in rural areas. However, after adjusted by age, the cancer incidence rate in urban was the same as that of rural areas. The crude mortality in Gansu province was 128.54/100,000 (135.04/100,000 in males and 124.43/100,000 in females), the age-standardized mortality rates by Chinese standard population (ASMRC) and by world standard population (ASMRW) were 109.54/100,000 and 108.44/100,000, respectively, and the cumulative mortality rate (0.74 years old) was 12.91%. The crude cancer mortality rate in urban areas was higher than that of rural areas. However, the agestandardized rate in urban areas was the same as that of rural areas. Cancers of stomach, liver, lung, esophagus, female breast, colorectum, cervix, brain, pancreas and ovary were the most common cancers, accounting for about 83.56% of all cancer new cases. Stomach cancer, liver cancer, lung cancer, esophageal cancer, female breast cancer, colorectal cancer, brain cancer, lymphoma, pancreatic cancer and cervix cancer were the leading causes of cancer death, accounting for about 85.58% of all cancer deaths. The burden between urban and rural, males and females was different.

conclusionsRegistration data of Gansu province were qualified to provide basic information on population-based cancer incidence, mortality for cancer prevention and control. The digestive tract cancer burden in Gansu province, especially for males in rural areas, was higher. The incidence rate of female breast cancer was higher in urban areas. Targeted prevention, early detection and treatment programs should be carried out by health department to control the cancer burden.

Indexed as

Cancer registryepidemiologyGansu provinceincidencemortality

Identifiers

PMID27478315
PMCPMC4949275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.